Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives $101.86 Average Price Target from Brokerages

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have earned an average recommendation of “Moderate Buy” from the eleven ratings firms that are covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $101.8571.

LNTH has been the topic of several research analyst reports. William Blair reaffirmed an “outperform” rating on shares of Lantheus in a report on Tuesday, March 17th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Lantheus in a report on Tuesday, May 26th. Truist Financial reaffirmed a “buy” rating and issued a $115.00 price target (up from $98.00) on shares of Lantheus in a report on Monday, May 11th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $94.00 price target on shares of Lantheus in a report on Thursday, May 7th. Finally, Wall Street Zen cut shares of Lantheus from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in LNTH. Vanguard Group Inc. grew its position in Lantheus by 1.7% in the third quarter. Vanguard Group Inc. now owns 6,952,418 shares of the medical equipment provider’s stock worth $356,590,000 after acquiring an additional 115,338 shares in the last quarter. M&T Bank Corp purchased a new position in Lantheus in the fourth quarter worth $370,950,000. Farallon Capital Management LLC grew its position in Lantheus by 56.1% in the fourth quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock worth $361,199,000 after acquiring an additional 1,950,252 shares in the last quarter. Reinhart Partners LLC. grew its position in Lantheus by 15.9% in the fourth quarter. Reinhart Partners LLC. now owns 1,562,576 shares of the medical equipment provider’s stock worth $103,990,000 after acquiring an additional 214,820 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in Lantheus by 3.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,415,463 shares of the medical equipment provider’s stock worth $94,202,000 after acquiring an additional 44,374 shares in the last quarter. Institutional investors own 99.06% of the company’s stock.

Lantheus Trading Down 0.2%

Shares of LNTH stock opened at $109.58 on Tuesday. The company’s fifty day simple moving average is $96.39 and its two-hundred day simple moving average is $80.34. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.83 and a quick ratio of 2.64. Lantheus has a 1 year low of $47.25 and a 1 year high of $111.46. The stock has a market capitalization of $7.13 billion, a price-to-earnings ratio of 26.40 and a beta of -0.03.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.25 by $0.21. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The business had revenue of $377.33 million for the quarter, compared to analysts’ expectations of $354.48 million. During the same quarter in the previous year, the firm posted $1.53 EPS. The business’s revenue for the quarter was up 1.2% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, analysts anticipate that Lantheus will post 4.49 earnings per share for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.